MCQ 22 Nov 2023

Daily Static MCQs for CLAT Prelims Exams - (22 November 2023)



Moving closer to being able to develop the country’s first vaccine against dengue, drug-makers Serum Institute of India and [1] have applied to the Indian Council of Medical Research’s (ICMR) call for ‘Expression of Interest’ for collaborative Phase-III clinical trials for indigenous manufacturers. Phase-III clinical trial is being done for evaluation of efficacy, along with safety and immunogenicity of tetravalent dengue vaccine candidate developed by Indian manufacturers. According to ICMR, dengue virus disease causes significant morbidity and mortality across the globe. In India, 2 to 2.5 lakh cases are reported annually. The global incidence of dengue has grown dramatically with about half of the world’s population now at risk. Although an estimated 100-400 million infections occur each year, over 80% are generally mild and asymptomatic. Hence, the World Health Organization (WHO) has identified dengue to be one among the top ten global health threats in 2019. As of now, there is no specific treatment for dengue/severe dengue. Meanwhile, giving details about the two potential vaccines, Dr. Nivedita Gupta, the Head of Virology, ICMR, said that Serum Institute of India’s vaccine initiated 1/2 studies in paediatric population and the plan for vaccine is to conduct Phase-III randomised, double-blind, placebo- controlled trial in 10,335 healthy adults (aged 18-80 years) in 20 sites (ICMR-funded). The Phase- III protocol has been approved by Drugs Controller General of India and the company is trying to upscale vaccine production with the trials this year. ICMR has noted that the desirable characteristics of a dengue vaccine includes acceptable short- and long-term safety profile (no antibody dependent enhancement), inducing protection against all four serotypes of dengue, reducing risk of severe diseases and deaths, inducing a sustained immune response and effectiveness irrespective of the earlier sero-status and age of the individual.

Question1:- Which drug maker company along with Serum Institute of India have applied to the Indian Council of Medical Research (ICMR) call for Expression of Interest for collaborative Phase-III clinical trials for indigenous manufacturers, redacted as [1] in the above passage?
  • A. GlaxoSmithKline Pharmaceuticals
  • B. Panacea biotech ltd.
  • C. Bharat Serums and Vaccines ltd
  • D. Biocon Ltd
Answer is B is correct. Moving closer to being able to develop the countrys first vaccine against dengue, drug-makers Serum Institute of India and Panacea Biotec have applied to the Indian Council of Medical Researchs (ICMR) call for Expression of Interest for collaborative Phase-III clinical trials for indigenous manufacturers. Hence, b is the correct option.
Question2:-Which is the world’s first and India’s indigenously developed vaccine for Covid-19?
  • A. ZyCoV-D
  • B. Corbevax
  • C. INCOVACC
  • D. Mynvax
Answer is A is correct. The ZyCoV-D is the world’s first and India’s indigenously developed DNA based vaccine for COVID-19 to be administered in humans including children and adults 12 years and above. This vaccine has been developed in partnership with the Department of Biotechnology (DBT), Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, a PSU of DBT. Hence, a is the correct option.
Question3:-Dengue is a mosquito-borne tropical disease caused by which virus?
  • A. Rhinovirus
  • B. Genus Flavivirus
  • C. Paramyxovirus
  • D. Variola virus
Answer is B is correct. Dengue is a mosquito-borne tropical disease caused by the dengue virus (Genus Flavivirus), transmitted by several species of female mosquito within the genus Aedes, principally Aedes aegypti. This mosquito also transmits chikungunya, yellow fever and Zika infection. Hence, b is the correct option.
Question4:-Which is the first country in world that has authorized the use of Plant based COVID19 vaccine?
  • A. India
  • B. Canada
  • C. China
  • D. USA
Answer is B is correct. The first country in the world that has authorized the use of a plant-based COVID-19 vaccine is Canada. The two-dose vaccine of Medicago can be given to adults who are aged between 18 to 64, but little data is available on the shots received by people aged 65 and above. Hence, b is the correct option.
Question5:-Which is the first indigenously developed human papillomavirus vaccine has been launched on the occasion of National Girl Child Day 2023?
  • A. CERVIVAX
  • B. CERVAVAC
  • C. CERVIVACC
  • D. None of the above
Answer is B is correct. On the occasion of National Girl Child Day, the Serum Institute of India on Tuesday launched the first indigenously developed human papillomavirus vaccine (HPV) “CERVAVAC, against the cervical cancer in women. Hence, b is the correct option.